| Product Name |
HIV |
HIV-1 |
HIV-2 |
Purity |
| Chloroquine |
|
|
|
99.50% |
| Doxorubicin hydrochloride |
|
|
|
99.90% |
| 5-Fluorouracil |
|
|
|
99.99% |
| F9170 TFA |
|
|
|
99.70% |
| Chloroquine phosphate |
|
|
|
99.89% |
| Plerixafor |
|
|
|
99.90% |
| Panobinostat |
|
|
|
99.37% |
| Hydroxyurea |
|
|
|
99.34% |
| Maraviroc |
|
HIV-1 (Ba-L), IC50: 1.1 nM (in PM-1 cells)
|
|
99.98% |
| Ivermectin |
|
|
|
98.28% |
| CK-666 |
|
|
|
99.95% |
| Ebselen |
|
|
|
99.91% |
| Plerixafor octahydrochloride |
|
|
|
99.09% |
| Scutellarin |
|
|
|
99.04% |
| Rottlerin |
|
|
|
98.45% |
| Betulinic acid |
|
|
|
99.06% |
| ONX-0914 |
|
|
|
99.72% |
| Zidovudine |
|
|
|
99.97% |
| Efavirenz |
|
|
|
99.93% |
| Lopinavir |
|
|
|
99.71% |
| Tenofovir |
|
|
|
99.92% |
| Nelfinavir |
|
|
|
98.65% |
| Nevirapine |
|
|
|
99.93% |
| Emtricitabine |
|
|
|
99.97% |
| Dolutegravir |
|
|
|
99.85% |
| 3-Deazaadenosine |
|
|
|
≥99.0% |
| α-Lipoic Acid |
|
|
|
99.86% |
| TAK-779 |
|
R5 HIV-1 (KK), EC50: 1.6 nM (in PBMCs)
R5 HIV-1 (KK), EC90: 20.8 nM (in PBMCs)
R5 HIV-1 (CTV), EC50: 3.5 nM (in PBMCs)
R5 HIV-1 (CTV), EC90: 27 nM (in PBMCs)
R5 HIV-1 (HHA), EC50: 3.2 nM (in PBMCs)
R5 HIV-1 (HHA), EC90: 7.5 nM (in PBMCs)
R5 HIV-1 (Ba-L), EC50: 1.2 nM (in MAGI-CCR5 cells)
R5 HIV-1 (Ba-L), EC50: 3.7 nM (in PBMCs)
R5 HIV-1 (Ba-L), EC90: 5.7 nM (in MAGI-CCR5 cells)
R5 HIV-1 (Ba-L), EC90: 12.8 nM (in PBMCs)
|
|
99.89% |
| Lenacapavir |
|
|
|
98.44% |
| Tenofovir Disoproxil fumarate |
|
|
|
99.65% |
| Raltegravir |
|
|
|
99.93% |
| Tenofovir alafenamide |
|
|
|
99.93% |
| Bictegravir |
|
|
|
99.93% |
| Theaflavin 3,3'-digallate |
|
|
|
99.73% |
| Stavudine |
|
|
|
99.87% |
| Cobicistat |
|
|
|
99.77% |
| Rilpivirine |
|
|
|
99.25% |
| Fangchinoline |
|
|
|
99.92% |
| Cenicriviroc |
|
R5 HIV-1, IC50: 0.024-0.08 nM (in PBMCs)
|
R5 HIV-2, IC50: 0.03-0.98 nM (in PBMCs)
|
99.51% |
| BRD-K98645985 |
|
|
|
98.67% |
| Tat-beclin 1 |
|
|
|
99.89% |
| Enfuvirtide |
|
|
|
99.93% |
| Darunavir |
|
|
|
99.91% |
| Sennoside A |
|
|
|
99.66% |
| Limonin |
|
|
|
99.38% |
| Miltefosine |
|
|
|
99.92% |
| Mavorixafor trihydrochloride |
|
HIV-1 (NL4.3 strain), IC50: 1 nM (in MT-4 cells)
HIV-1 (NL4.3 strain), IC50: 9 nM (in PBMCs)
HIV-1 (NL4.3 strain), IC90: 3 nM (in MT-4 cells)
HIV-1 (NL4.3 strain), IC90: 26 nM (in PBMCs)
|
|
99.75% |
| Indinavir sulfate |
|
|
|
99.97% |
| Elvitegravir |
|
|
|
99.90% |
| Obefazimod |
|
HIV-1, IC50: 0.1-0.5 μM (in PBMCs)
|
|
99.85% |
| Doravirine |
|
|
|
99.79% |
| 5-(N,N-Hexamethylene)-amiloride |
|
|
|
99.14% |
| Sparstolonin B |
|
|
|
99.94% |
| Triciribine |
|
HIV-1, IC50: 0.02-0.46 μM
|
HIV-2, IC50: 0.02-0.46 μM
|
99.81% |
| Atazanavir |
|
|
|
99.86% |
| IT1t dihydrochloride |
|
HIV-1 (X4), IC50: 14.2 nM (in MT-4 cells)
HIV-1 (X4), IC50: 19 nM (in PBMCs)
|
|
99.77% |
| BRD3308 |
|
|
|
98.34% |
| Tizoxanide |
|
|
|
98.10% |
| Nelfinavir Mesylate |
|
|
|
98.93% |
| Tipranavir |
|
|
|
≥98.0% |
| Bromosporine |
|
|
|
99.89% |
| Ro24-7429 |
|
|
|
99.85% |
| Tenofovir alafenamide fumarate |
|
|
|
99.87% |
| Temsavir |
|
|
|
98.70% |
| BRD-6929 |
|
|
|
99.01% |
| Pentosan Polysulfate (Sodium) (W/W 43%) |
|
|
|
|
| Etravirine |
|
|
|
99.07% |
| 9-Aminoacridine |
|
|
|
99.35% |
| Trilobatin |
|
|
|
98.97% |
| DAPTA |
|
|
|
98.87% |
| 2-Hydroxycinnamic acid |
|
|
|
99.86% |
| Methyl gallate |
|
|
|
99.98% |
| Azvudine |
|
HIV-1, EC50: 0.03-6.92 nM
|
HIV-2, EC50: 0.018-0.02 nM
|
99.79% |
| Cenicriviroc Mesylate |
|
R5 HIV-1, IC50: 0.024-0.08 nM (in PBMCs)
|
R5 HIV-2, IC50: 0.03-0.98 nM (in PBMCs)
|
98.84% |
| Cyclotriazadisulfonamide |
|
|
|
98.45% |
| L-Chicoric Acid |
|
|
|
99.85% |
| TAT peptide TFA |
|
|
|
99.83% |
| PF-3450074 |
|
HIV-1 (NL4.3 strain), IC50: 0.72 μM
|
|
98.89% |
| Tenofovir Disoproxil |
|
|
|
99.52% |
| Diphyllin |
|
|
|
99.90% |
| 3-Deazaadenosine hydrochloride |
|
|
|
99.67% |
| Atazanavir sulfate |
|
|
|
99.68% |
| Apelin-17(human, bovine) |
|
|
|
98.29% |
| Dolutegravir sodium |
|
|
|
99.97% |
| Islatravir |
|
HIV-1 (WT), EC50: 0.068 nM
HIV-1 (MDR), EC50: 0.15 nM
HIV-1 (M184V), EC50: 3.1 nM
|
|
99.67% |
| Chloroquine dihydrochloride |
|
|
|
99.61% |
| α-Lipoic Acid-d5 |
|
|
|
|
| Ibalizumab |
|
|
|
99.27% |
| TAT TFA |
|
|
|
99.70% |
| Chloroquine phosphate (Standard) |
|
|
|
|
| Fumagillin |
|
|
|
≥99.0% |
| Bromhexine hydrochloride |
|
|
|
99.93% |
| Bryostatin 1 |
|
|
|
99.70% |
| TAT |
|
|
|
99.92% |
| α-Lipoic Acid sodium |
|
|
|
99.92% |
| Censavudine |
|
|
|
98.71% |
| Fosamprenavir |
|
|
|
98.0% |
| Apelin-36(human) |
|
|
|
98.05% |
| CDK9-IN-1 |
|
|
|
98.52% |
| TC14012 |
|
|
|
98.92% |
| Azvudine hydrochloride |
|
HIV-1, EC50: 0.03-6.92 nM
|
HIV-2, EC50: 0.018-0.02 nM
|
99.19% |
| DDX3-IN-2 |
|
|
|
99.36% |
| 2',3'-Dideoxyadenosine |
|
|
|
99.96% |
| PF-00835231 |
|
|
|
99.31% |
| HIV-1 TAT (48-60) |
|
|
|
99.80% |
| Oleanonic acid |
|
|
|
99.63% |
| Delavirdine mesylate |
|
|
|
98.65% |
| FC131 TFA |
|
|
|
99.87% |
| Fostemsavir |
|
|
|
99.69% |
| AMD 3465 hexahydrobromide |
|
X4 HIV-1 (IIIB), IC50: 12.3 nM (in MT-4 cells)
X4 HIV-1 (RF), IC50: 7.4 nM (in MT-4 cells)
X4 HIV-1 (HE), IC50: 9.8 nM (in MT-4 cells)
X4 HIV-1 (NL4.3), IC50: 6.1 nM (in MT-4 cells)
X4 HIV-1 (NL4.3AMD3100), IC50: 2822 nM (in MT-4 cells)
|
HIV-2 (ROD), IC50: 12.3 nM (in MT-4 cells)
HIV-2 (EHO), IC50: 12.3 nM (in MT-4 cells)
|
98.0% |
| Peptide T |
|
|
|
98.06% |
| Bictegravir sodium |
|
|
|
99.10% |
| Decanoyl-RVKR-CMK TFA |
|
|
|
98.04% |
| Stampidine |
|
|
|
99.96% |
| TAK-220 |
|
HIV-1 (CTV), EC50: 0.72 nM (in PBMCs)
HIV-1 (CTV), EC90: 5 nM (in PBMCs)
HIV-1 (KK), EC50: 1.2 nM (in PBMCs)
HIV-1 (KK), EC90: 12 nM (in PBMCs)
HIV-1 (HNK), EC50: 1.7 nM (in PBMCs)
HIV-1 (HNK), EC90: 28 nM (in PBMCs)
HIV-1 (HHA), EC50: 0.55 nM (in PBMCs)
HIV-1 (HHA), EC90: 4 nM (in PBMCs)
HIV-1 (HKW), EC50: 1.7 nM (in PBMCs)
HIV-1 (HKW), EC90: 12 nM (in PBMCs)
HIV-1 (HTN), EC50: 0.93 nM (in PBMCs)
HIV-1 (HTN), EC90: 15 nM (in PBMCs)
|
|
99.95% |
| Soyasaponin II |
|
|
|
99.81% |
| TAT (48-57) |
|
|
|
98.23% |
| Darunavir Ethanolate |
|
|
|
99.93% |
| Alizarin complexone |
|
|
|
98.0% |
| Delavirdine |
|
|
|
99.70% |
| AMD 3465 |
|
X4 HIV-1 (IIIB), IC50: 12.3 nM (in MT-4 cells)
X4 HIV-1 (RF), IC50: 7.4 nM (in MT-4 cells)
X4 HIV-1 (HE), IC50: 9.8 nM (in MT-4 cells)
X4 HIV-1 (NL4.3), IC50: 6.1 nM (in MT-4 cells)
X4 HIV-1 (NL4.3AMD3100), IC50: 2822 nM (in MT-4 cells)
|
HIV-2 (ROD), IC50: 12.3 nM (in MT-4 cells)
HIV-2 (EHO), IC50: 12.3 nM (in MT-4 cells)
|
99.59% |
| Celgosivir hydrochloride |
|
|
|
98.0% |
| Vicriviroc maleate |
|
HIV-1 (JrFL), IC90: 3.3 nM (in PBMC cells)
HIV-1 (ADA-M), IC90: 2.8 nM (in PBMC cells)
HIV-1 (301657), IC90: 1.8 nM (in PBMC cells)
HIV-1 (JV1083), IC90: 4.9 nM (in PBMC cells)
HIV-1 (RU 570), IC90: 10 nM (in PBMC cells)
|
|
99.91% |
| Apelin-12 |
|
|
|
99.83% |
| Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside |
|
|
|
99.09% |
| NF279 |
|
|
|
98.5% |
| Tenofovir alafenamide hemifumarate |
|
|
|
99.92% |
| ONX-0914 TFA |
|
|
|
98.01% |
| Elsulfavirine |
|
|
|
99.90% |
| Fosamprenavir Calcium Salt |
|
|
|
99.88% |
| Zingibroside R1 |
|
|
|
99.75% |
| LDC4297 hydrochloride |
|
HIV-1 (NL4.3 strain), EC50: 1.04 μM
4LIG7, EC50: 1.13 μM
|
|
98.23% |
| Indinavir |
|
|
|
99.96% |
| Ulonivirine |
|
|
|
98.61% |
| Thiamine disulfide |
|
|
|
99.54% |
| HIV-1 inhibitor-6 |
|
X4 HIV-1 (IIIB), EC50: 0.6 μM
R5 HIV-1, EC50: 0.9 μM
|
|
99.10% |
| Aplaviroc hydrochloride |
|
HIV-1Ba-L, IC50: 0.4 nM
HIV-1JRFL, IC50: 0.1 nM
HIV-1MOKW, IC50: 0.2 nM
|
|
99.94% |
| 2-Hydroxyacetophenone |
|
|
|
99.90% |
| Panobinostat lactate |
|
|
|
98.67% |
| Fostemsavir Tris |
|
|
|
99.78% |
| Ingenol-3-palmitate |
|
|
|
99.65% |
| Tenofovir hydrate |
|
|
|
99.53% |
| Dapivirine |
|
|
|
99.80% |
| Apelin-36(rat, mouse) |
|
|
|
99.12% |
| Mavorixafor hydrochloride |
|
HIV-1 (NL4.3 strain), IC50: 1 nM (In MT-4 cells)
HIV-1 (NL4.3 strain), IC50: 9 nM (In PBMCs)
HIV-1 (NL4.3 strain), IC90: 3 nM (In MT-4 cells)
HIV-1 (NL4.3 strain), IC90: 26 nM (In PBMCs)
|
|
99.10% |
| Fipravirimat dihydrochloride |
|
|
|
99.70% |
| Tenofovir exalidex |
|
|
|
99.82% |
| Erythromycin Ethylsuccinate |
|
|
|
98.0% |
| PTACH |
|
|
|
99.65% |
| HIV-1 inhibitor-45 |
|
|
|
99.54% |
| BMS-378806 |
|
|
|
98.94% |
| Mavorixafor |
|
HIV-1 (NL4.3 strain), IC50: 1 nM (in MT-4 cells)
HIV-1 (NL4.3 strain), IC50: 9 nM (in PBMCs)
HIV-1 (NL4.3 strain), IC90: 3 nM (in MT-4 cells)
HIV-1 (NL4.3 strain), IC90: 26 nM (in PBMCs)
|
|
99.47% |
| Claficapavir |
|
|
|
98.75% |
| FGI-106 tetrahydrochloride |
|
|
|
99.68% |
| GSK3532795 |
|
|
|
99.59% |
| α-Lipoic Acid (Standard) |
|
|
|
|
| DPC-681 |
|
|
|
99.72% |
| Hck-IN-1 |
|
HIV-1 Nef, IC50: 100-300 nM
|
|
98.10% |
| Salicylanilide |
|
|
|
99.20% |
| Nifeviroc |
|
|
|
98.94% |
| Azulene |
|
|
|
99.98% |
| Gomisin M2 |
|
|
|
99.75% |
| Gomisin M1 |
|
|
|
99.56% |
| Ethyl salvianolate A |
|
|
|
|
| Chloroquine-d5 |
|
|
|
99.90% |
| Rovafovir etalafenamide |
|
|
|
99.85% |
| Corydine |
|
|
|
99.93% |
| KRH-3955 hydrochloride |
|
X4 HIV-1NL4-3, EC50: 0.3-1.0 nM
|
|
|
| Formycin A |
|
|
|
99.0% |
| NBD-556 |
|
|
|
99.57% |
| Aeroplysinin 1 |
|
|
|
|
| HIV-1 integrase inhibitor |
|
|
|
|
| Leptomycin A |
|
|
|
|
| Suvizumab |
|
HIV-189.6, IC50: 0.2 μg/mL
HIV-1MN, IC50: 0.1 μg/mL
HIV-1SF2, IC50: 1.0 μg/mL
|
|
≥99.0% |
| FNC-TP |
|
|
|
99.92% |
| NBD-14270 |
|
|
|
99.53% |
| SARS-CoV-IN-2 |
|
|
|
98.66% |
| Doxorubicin |
|
|
|
|
| Fipravirimat |
|
|
|
|
| Celgosivir |
|
|
|
|
| SARS-CoV-IN-3 |
|
|
|
99.36% |
| HIV-1 inhibitor-8 |
|
HIV-1 (WT), IC50: 0.081 μM
|
|
98.03% |
| Reverse transcriptase-IN-1 |
|
|
|
98.08% |
| FC131 |
|
|
|
|
| IT1t |
|
HIV-1 (X4), IC50: 14.2 nM (in MT-4 cells)
HIV-1 (X4), IC50: 19 nM (in PBMCs)
|
|
|
| FC-14369 |
|
|
|
|
| β-Rubromycin |
|
|
|
|
| 3'-Azido-3'-deoxy-5-methylcytidine |
|
HIV-1, EC50: 0.06 μM (in PBM cells)
|
|
99.90% |
| FNC-TP trisodium |
|
|
|
|
| Apricitabine |
|
|
|
|
| Apelin-36(human) TFA |
|
|
|
99.42% |
| 3′-Azido-2′,3′-dideoxyuridine |
|
|
|
99.11% |
| EFdA-TP tetrasodium |
|
|
|
|
| ICeD-2 |
|
|
|
|
| Aplaviroc |
|
HIV-1Ba-L, IC50: 0.4 nM
HIV-1JRFL, IC50: 0.1 nM
HIV-1MOKW, IC50: 0.2 nM
|
|
|
| EFdA-TP tetraammonium |
|
|
|
98.03% |
| Pentosan Polysulfate |
|
|
|
|
| IQP-0528 |
|
|
|
99.90% |
| Emtricitabine S-oxide |
|
|
|
|
| AzddMeC |
|
HIV-1, EC50: 9 nM (Human PBM cells)
HIV-1, EC50: 6 nM (Human macrophages)
|
|
98.96% |
| NBD-557 |
|
|
|
99.41% |
| (Z)-9-Propenyladenine |
|
|
|
98.02% |
| FGI-106 |
|
|
|
|
| NBD-14189 |
|
|
|
99.84% |
| HIV-1 inhibitor-33 |
|
|
|
|
| Raltegravir sodium |
|
|
|
|
| DENV-IN-6 |
|
|
|
|
| HIV-1 inhibitor-49 |
|
HIV-1 (WT), EC50: 17 nM
HIV-1 (L100I), EC50: 0.38 μM
HIV-1 (K103N), EC50: 2.64 μM
HIV-1 (Y181C), EC50: 1.85 μM
HIV-1 (E138K), EC50: 0.09 μM
|
|
|
| PF-46396 |
|
|
|
|
| HIV-1 inhibitor-13 |
|
HIV-1 (WT), EC50: 2.85 ± 1.1 nM
|
|
|
| HIV-1 inhibitor-41 |
|
HIV-1 (WT), IC50: 20.8 nM
HIV-1 (E138K), IC50: 50 nM
HIV-1 (L100I), IC50: 1.03 μM
HIV-1 (K103N), IC50: 3.39 μM
HIV-1 (Y181C), IC50: 0.75 μM
HIV-1 (Y188L), IC50: 69.04 μM
|
|
|
| BMS 561390 |
|
HIV-1 (WT), IC50: 2.0 nM
HIV-1 (K103N), IC50: 21 nM
HIV-1 (L100I), IC50: 5.9 nM
|
|
|
| Hinnuliquinone |
|
|
|
|
| Cys-TAT(47-57) |
|
|
|
|
| HIV-1 protease-IN-4 |
|
|
|
|
| Temporin-SHa |
|
|
|
|
| HIV-1 inhibitor-64 |
|
|
|
|
| Patentiflorin A |
|
|
|
|
| Apelin-36(rat, mouse) TFA |
|
|
|
|
| Dexelvucitabine |
|
|
|
99.52% |
| HIV-IN-5 |
|
HIV-1, IC50: 0.16 ± 0.0 μM
HIV-1 (Y181C), IC50: >100 μM
HIV-1 (K103N), IC50: >100 μM
|
|
|
| Fosamprenavir-d4 |
|
|
|
|
| HIV-1 inhibitor-21 |
|
HIV-1 (WT), EC50: 12.7 nM
HIV-1 (K103N), EC50: 10.4 nM
|
|
|
| DENV-IN-5 |
|
HIV (IIIB), EC50: 0.1512 μM
|
|
|
| HIV-1 inhibitor-40 |
|
HIV-1 (E138K), EC50: 0.009 μM
HIV-1 (Y181C), EC50: 0.029 μM
HIV-1 (Y188L), EC50: 0.570 μM
HIV-1 (K103N), EC50: 0.004 μM
HIV-1 (L100I), EC50: 0.019 μM
HIV-1 (WT), EC50: 1.9 nM
|
|
|
| HIV-1 protease-IN-6 |
|
|
|
|
| ZLM-66 |
|
HIV-1 (E138K), EC50: 25 nM
HIV-1 (F227L+V106A), EC50: 27530 nM
HIV-1 (Y181C), EC50: 58 nM
HIV-1 (K103N+Y181C), EC50: 260 nM
HIV-1 (K103N), EC50: 13 nM
HIV-1 (L100I), EC50: 24 nM
HIV-1 (WT), EC50: 13 nM
|
|
|
| 4'-Ethynyl-2'-deoxyadenosine |
|
|
|
|
| CXCR4 antagonist 1 |
|
|
|
|
| Indinavir sulfate ethanolate |
|
|
|
|
| Azt-pmap |
|
|
|
|
| Inophyllum B |
|
|
|
|
| HIV-1 inhibitor-51 |
|
HIV-1 (E138K), EC50: 9.77 nM
HIV-1 (F227L+V106A), EC50: 19.8 nM
HIV-1 (Y181C), EC50: 10.2 nM
HIV-1 (RES056), EC50: 53.3 nM
HIV-1 (Y188L), EC50: 13.2 nM
HIV-1 (K103N), EC50: 2.87 nM
HIV-1 (L100I), EC50: 3.04 nM
HIV-1 (WT), IC50: 0.03 μM
HIV-1 (WT), Kd: 2.5 μM
|
|
|
| HIV-1 inhibitor-42 |
|
HIV-1, IC50: 0.06 ± 0.0 μM
HIV-1 (Y181C), IC50: 15.510 ± 1 μM
HIV-1 (K103N), IC50: 53.045 ± 6 μM
|
|
|
| HIV-1 inhibitor-25 |
|
HIV-1 (E138K), EC50: 0.1961 ± 0 μM
HIV-1 (F227L+V106A), EC50: 3.0683 ± 0 μM
HIV-1 (Y181C), EC50: 0.5075 ± 0 μM
HIV-1 (Y188L), EC50: 5.8136 ± 2 μM
HIV-1 (K103N), EC50: 0.4383 ± 0 μM
HIV-1 (L100I), EC50: 1.2458 ± 0 μM
HIV (IIIB), EC50: 13.6 nM
|
|
|
| Atazanavir-d15 |
|
|
|
|
| HIV-1 capsid inhibitor 1 |
|
|
|
|
| Kadsuracoccinic acid A |
|
|
|
|
| PROTAC Vif degrader-1 |
|
HIV (IIIB), EC50: 33.35 μM
|
|
|
| HIV-1 inhibitor-34 |
|
|
|
|
| HIV-1 inhibitor-39 |
|
|
|
|
| HIV-1 inhibitor-43 |
|
HIV-1 (Y188L), EC50: 21.3 nM
HIV-1 (K103N+Y181C), EC50: 6.2 nM
HIV-1 (K103N), EC50: <0.7 nM
HIV-1 (Y181C), EC50: <0.7 nM
|
|
|
| Siamycin I |
|
|
|
|
| HIV-1 Nef-IN-1 |
|
|
|
98.60% |
| HIV-1 inhibitor-29 |
|
HIV (IIIB), EC50: 2.18 μM
HIV-1 (F227L/V106A), EC50: 0.974 μM
|
|
|
| HIV-1 inhibitor-28 |
|
|
|
|
| HIV-1 inhibitor-50 |
|
HIV-1 (E138K), EC50: 9.77 nM
HIV-1 (F227L+V106A), EC50: 19.8 nM
HIV-1 (Y181C), EC50: 10.2 nM
HIV-1 (Y188L), EC50: 13.2 nM
HIV-1 (K103N), EC50: 2.87 nM
HIV-1 (L100I), EC50: 3.04 nM
HIV-1 (WT), EC50: 3.04 nM
|
|
|
| Fozivudine tidoxil |
|
|
|
|
| BMS-585248 |
|
|
|
|
| HIV-1 inhibitor-18 |
|
HIV-1 NL4-3, EC50: 5.14 μM
|
|
|
| Des(benzylpyridyl) Atazanavir |
|
|
|
|
| TC14012 TFA |
|
|
|
|
| Apelin-17(human, bovine) TFA |
|
|
|
|
| HIV-1 inhibitor-27 |
|
HIV-1 YU2, IC50: 16 μM
HIV-1 NL4-3, IC50: 0.5 μM
HIV-1 89.6, IC50: 0.39 μM
|
|
|
| Myriceric acid B |
|
HIV-1, IC50: 8.3±0.2 μg/mL (infection of HIV-1 Env pseudovirus)
|
|
|
| CXCR4 antagonist 4 |
|
|
|
|
| Orthosporin |
|
|
|
|
| Wikstrol A |
|
|
|
|
| HIV-1 inhibitor-15 |
|
HIV-1 (WT), EC50: 1.7 nM
HIV-1 (L100I), EC50: 4 nM
HIV-1 (K103N), EC50: 2 nM
HIV-1 (Y181C), EC50: 6 nM
HIV-1 (E138K), EC50: 9 nM
|
|
|
| Fuscin |
|
|
|
|
| HIV-1 inhibitor-32 |
|
|
|
|
| HIV-1 inhibitor-80 |
|
|
|
|
| Sennoside A (Standard) |
|
|
|
|
| AL-470 |
|
|
|
|
| F9170 |
|
|
|
|
| SAMT-247 |
|
|
|
|
| Fosamprenavir sodium |
|
|
|
|
| HF50731 |
|
|
|
|
| Efavirenz-13C6 |
|
|
|
|
| TAT (48-57) (TFA) |
|
|
|
|
| HIV-1 inhibitor-16 |
|
HIV-1 (WT), EC50: 1.3 nM
HIV-1 (K103N), EC50: 5.4 nM
HIV-1 (E138K), EC50: 9.2 nM
HIV-1 (Y181C), EC50: 22 nM
HIV-1 (L100I), EC50: 35 mM
|
|
|
| HIV Capsid-IN-2 |
|
|
|
|
| HGS004 |
|
|
|
|
| HIV-1 inhibitor-54 |
|
|
|
|
| Atazanavir-d18 |
|
|
|
|
| BEA 005 |
|
|
|
|
| DMJ-I-228 |
|
|
|
|
| Reverse transcriptase-IN-3 |
|
HIV-1 (E138K), EC50: 0.734 μM
HIV-1 (F227L+V106A), EC50: 34 nM
HIV-1 (Y181C), EC50: 45 nM
HIV-1 (RES056), EC50: 42 nM
HIV-1 (Y188L), EC50: 35 nM
HIV-1 (K103N), EC50: 9 nM
HIV-1 (L100I), EC50: 65 nM
HIV (IIIB), EC50: 8 nM
|
|
|
| WRNA10 |
HIV, IC50: 10 μM (CC50: 40 μM[1])
|
|
|
|
| DPC 684 |
|
|
|
|
| UC-781 |
|
|
|
|
| HIV-1 inhibitor-24 |
|
|
|
|
| HIV-1 inhibitor-46 |
|
|
|
|
| HIV-1 inhibitor-74 |
|
HIV-1 (WT), IC50: 0.134 μM
HIV (IIIB), EC50: 0.0047 μM
|
|
|
| [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) |
|
|
|
|
| INCB9471 |
|
|
|
|
| Fosdevirine |
|
HIV-1 (K103N)
HIV-1 (Y181C)
HIV-1
|
|
98.96% |
| gp120-IN-1 |
|
HIV-1, IC50: 2.2 μM
HIV-1, CC50: 100.90 μM
|
|
|
| HIV-1 inhibitor-12 |
|
|
|
|
| Mozenavir |
|
|
|
|
| HIV-1 inhibitor-17 |
|
HIV-1 NL4-3, EC50: 2.57 μM
|
|
|
| gp120-IN-2 |
|
HIV-1, IC50: 7.5 μM
HIV-1, CC50: 112.93 μM
|
|
|
| H-Gly-Pro-Gly-NH2 |
|
|
|
|
| NNRT-IN-8 |
|
HIV-1 (WT), EC50: 0.0014 μM
RT-K103N, EC50: 0.0041 μM
HIV-1 (E138K), EC50: 0.0077 μM
|
|
|
| Aureothin |
|
|
|
|
| Antiviral agent 9 |
|
|
|
|
| HIV-1 inhibitor-22 |
|
HIV-1 (WT), EC50: 0.304 μM
HIV-1 (K103N), EC50: 0.201 μM
|
|
|
| Nevirapine-d4 |
|
|
|
|
| CI-39 |
|
HIV-1 (WT), EC50: 3.40 μM
HIV-1 (WT), CC50: >30 μM
|
|
|
| Tat-beclin 1 TFA |
|
|
|
|
| EFdA-TP |
|
|
|
|
| HI-280 |
|
|
|
|
| soVIRIP |
|
|
|
|
| Luzopeptin A |
|
|
|
|
| Fosamprenavir Calcium Salt (Standard) |
|
|
|
|
| Calcium mesoxalate |
|
|
|
|
| Ancriviroc |
|
|
|
|
| HIV-1 inhibitor-14 |
|
HIV-1 (E138K), EC50: 7.66 nM
HIV-1 (F227L+V106A), EC50: 5.79 nM
HIV-1 (Y181C), EC50: 8.91 nM
HIV-1 (K103N+Y181C), EC50: 27.9 nM
HIV-1 (Y188L), EC50: 7.66 nM
HIV-1 (K103N), EC50: 6.91 nM
HIV-1 (L100I), EC50: 12.4 nM
HIV-1 (WT), EC50: 6.17 nM
|
|
|
| CCR5 antagonist 3 |
|
HIV-1, EC50: 0.010 μM (In TZM-bl cells)
|
|
|
| HIV-1 inhibitor-23 |
|
HIV-1 (WT), EC50: 24.9 nM
HIV-1 (K103N), EC50: 10.4 nM
|
|
|
| Ophiobolin C |
|
|
|
|
| CCR5 antagonist 2 |
|
HIV-1, EC50: 11 nM (TZM-bl cell)
|
|
|
| HIV-1 inhibitor-44 |
|
|
|
|
| HIV-1 inhibitor-52 |
|
HIV-1 V362I/V370A, EC50: 2.0 nM
HIV-1 R361K/V362I/L363M, EC50: 4.5 nM
HIV-1 V370A, EC50: 3.0 nM
HIV-1 A326T/V362I/V370A, EC50: 4.3 nM
HIV-1 ΔV370, EC50: 5.1 nM
HIV-1 (WT), EC50: 1.6 nM
HIV-1 T332S/V362I/prR41G, EC50: 6.4 nM
|
|
|
| FC-14367 |
|
|
|
|
| Scirpusin A |
|
|
|
|
| Suberosol |
|
|
|
|
| L 738372 |
|
|
|
|
| JTK-101 |
|
|
|
|
| Stavudine sodium |
|
|
|
|
| HIV-1-IN-87 |
|
|
|
|
| HIV-1-IN-82 |
|
|
|
|
| Fosamprenavir-13C6 |
|
|
|
|
| Crotoniazide |
|
|
HIV-2 (ROD), EC50: 11 μg/mL
|
|
| NNRT-IN-10 |
|
HIV-1 (WT), EC50: 1.16 nM
|
|
|
| HIV-1 inhibitor-63 |
|
|
|
|
| NNRT-IN-12 |
|
HIV-1 RT, IC50: 0.107 μM
HIV-1 (L100I), EC50: 14.1 nM
RT-K103N, EC50: 5.03 nM
RT-Y181C, IC50: 7.64 nM
RT-Y188L, EC50: 27.1 nM
|
|
|
| HIV-1 inhibitor-76 |
|
|
|
|
| NNRT-IN-9 |
|
HIV-1 (WT), EC50: 55 nM
HIV-1 (E138K), EC50: 67 nM
HIV-1 (K103N+Y181C), EC50: 3910 nM
|
|
|
| ATPase-IN-6 |
|
|
|
|
| Tenofovir maleate |
|
|
|
|
| SDZ283-910 |
|
|
|
|
| PROTAC CG167 |
|
|
|
|
| HIV-1-IN-85 |
|
HIV-1 (E138K), EC50: 30 nM
HIV-1 (F227L+V106A), EC1.5: 2399 nM
HIV-1 (Y181C), EC50: 3.7 nM
HIV-1 (RES056), EC50: 277 nM
HIV-1 (Y188L), EC50: 231 nM
HIV-1 (K103N), EC50: 5.8 nM
HIV-1 (L100I), EC50: 9.2 nM
HIV-1 (WT), EC50: 3.7 nM
HIV-1, IC50: 72 nM
|
|
|
| IC-1k |
|
|
HIV-2 (ROD), EC50: 97.97 nM
|
|
| 7-Deaza-2',3'-dideoxyguanosine |
|
|
|
98.02% |
| CCR5 antagonist 1 |
|
|
|
|
| MPG, HIV related |
|
|
|
|
| Peptide T TFA |
|
|
|
|
| beta-L-D4A |
|
|
|
|
| HIV-1 Rev (34-50) |
|
|
|
|
| MIV-150 |
|
|
|
|
